Chemoembolization in the Management of Liver Tumors
Open Access
- 1 October 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 8 (5) , 425-437
- https://doi.org/10.1634/theoncologist.8-5-425
Abstract
Learning Objectives: After completing this course, the reader will be able to:Explain the anatomic and biologic rationale for using chemoembolization to treat tumors localized to the liver. Identify appropriate candidates for this treatment based upon tumor biology and patient characteristics. Anticipate and manage the toxicities and complications of chemoembolization. Discuss the variability in results reported in the literature from different centers and in different tumor types.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.comThe dual vascular supply of the liver affords a unique opportunity to explore intraarterial therapies for hepatic malignancies. Chemoembolization is a well-established technique combining intra-arterial chemotherapy with delivery of embolic agents in order to achieve an antitumor effect due to a high local concentration and prolonged dwell time of the drug, along with select ischemia. Many tumors, such as hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors, cause symptoms and death by local growth and destruction of the liver. While there are other methods capable of controlling small or isolated hepatic neoplasms, none are suitable for the majority of these patients. Chemoembolization can produce significant results in terms of tumor shrinkage in many of these patients, and there are studies to suggest a survival advantage in hepatocellular carcinoma. Toxicity, however, may be substantial, and patient selection is crucial in order to achieve the optimal benefit of this powerful technique for individual populations.Keywords
This publication has 101 references indexed in Scilit:
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?Journal of Hepatology, 1998
- The vascularity of colorectal liver metastasesEuropean Journal of Surgical Oncology, 1996
- Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinomaCancer, 1994
- Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolizationCancer, 1993
- A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaJournal of Hepatology, 1990
- Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liverCancer, 1983
- Complications of long term transbrachial hepatic arterial infusion chemotherapyAmerican Journal of Roentgenology, 1977